How to appeal an Aetna immune globulin (ivig/scig) for pidd denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for immune globulin (ivig/scig) for pidd

Cited policy: Aetna Clinical Policy Bulletin — Intravenous and Subcutaneous Immunoglobulins

PIDD diagnosis per Bonilla 2015 / IDF criteria. SCIG (Hizentra/Cuvitru/Xembify/Cutaquig) covered as alternative to IVIG. Dose typically 100-200 mg/kg SC weekly or biweekly. Reauth requires documented trough or symptomatic improvement.

How Aetna denies immune globulin (ivig/scig) for pidd — and how to counter it

Where Aetna pushes back: 1) Must fail IVIG before SCIG; 2) Home self-infusion not approved; 3) Patient preference insufficient.

Counter-arguments that hold up: Berger Clin Immunol 2008 + Mahlaoui SCIG QoL literature — SCIG is non-inferior to IVIG with steadier troughs and fewer systemic AEs; not second-line. Bonilla 2015 + AAAAI 2017 Eight Principles support route choice based on tolerability, access, and patient autonomy. Indications for SC: IV adverse reaction, poor venous access / PICC complications, distance to infusion center, pediatric, steady-state trough optimization. FDA-approved Hizentra Mar 4, 2010 with home self-infusion in label.

What Aetna typically denies for immune globulin (ivig/scig) for pidd

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For immune globulin (ivig/scig) for pidd, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the immune globulin (ivig/scig) for pidd treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Privigen (IVIG)
• Gamunex-C (IVIG)
• Octagam (IVIG)
• Gammagard Liquid (IVIG)
• Flebogamma DIF (IVIG)
• Bivigam (IVIG)

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.